Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Naloxegol: Additional Phase III data

Additional data from the double-blind, international Phase III KODIAC-05 trial in 700 OIC patients with non-cancer pain showed that 34.9% of patients receiving once-daily 12.5 oral naloxegol and 39.7% of patients receiving once-daily 25 mg oral naloxegol were OIC

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers